Genentech

Genentech, Inc. has made six vice president appointments: Jennifer Cook to vice president, market development; Ashraf Hanna, Ph.D., to vice president, alliance management and pipeline strategy support; Ann L. Lee, Ph.D., to vice president, process development; James P. Miller to vice president, South San Francisco biochemical manufacturing; Quinton C. Oswald to vice president, sales and marketing, tissue growth and repair; and Robert S. Quinn to vice president, CIT business and science applications.

In her new role, Ms. Cook will be responsible for managing five organizations: market planning, forecasting and business analysis, pricing and publication strategy, international operations and commercial communications. She will report to Ian T. Clark, executive vice president, commercial operations. Ms. Cook worked at Genentech in preclinical development from 1987 to 1992. Prior to that, she worked in product development, business development and project management at Prizm Pharmaceuticals before rejoining Genentech in 1997. Since 1997, she has held positions of increasing responsibility in the commercial operations group, most recently serving as the senior director, market development.

Working with business development, the project portfolio management group, and R&D, Dr. Hanna will be responsible for establishing, implementing and evaluating alliance management strategy and process. He will report to Susan Desmond-Hellmann, M.D., M.P.H., president, product development. Prior to joining the company, Dr. Hanna was vice president at Tanox, with responsibilities for strategic planning and business development. Prior to that, he worked for McKinsey and Co. and was a medical resident at Metrowest Medical Center.

Dr. Lee is responsible for the development, implementation and support of clinical and commercial production processes and technologies, reporting to Patrick Y. Yang, Ph.D., executive vice president, product operations. She joins the company from Merck, where she held several senior leadership positions in vaccine development in the company’s research laboratories and served most recently, as vice president, chemical technology and engineering in the manufacturing division.

Mr. Miller will be responsible for the production of clinical and commercial proteins using recombinant and bacterial cell technology. He will report to Timothy L. Moore, vice president, South San Francisco manufacturing. He joined the company from Centocor Biologics, a division of Johnson & Johnson, where he most recently served as general manager. He has held executive and senior positions at Wyeth and Chiron Corp., as well as a variety of manufacturing positions at Invitron Corp., Lever Brothers Co. and Schering-Plough.

Mr. Oswald will report to Ian T. Clark, executive vice president, commercial operations. In this role, Oswald will be responsible for sales and marketing for four distinct operating groups: Lucentis, Lytics, Nutropin and Pulmozyme. He joins the company from Novartis, where he held several leadership positions, including, most recently, senior vice president, Novartis Ophthalmics North America. While at Novartis, he also held senior vice president roles in global marketing and sales operations, as well as global sales. Prior to that, Mr. Oswald was president, Latin America and Canada worldwide medicines group at Bristol-Myers Squibb.

In this newly created position, Mr. Quinn will focus on a variety of IT solutions to support the company’s corporate and commercial functions, and R&D. Additionally, he will be responsible for building the company’s enterprise IT systems and improving business processes. He joins the company from KLA-Tencor, where he served as vice president and chief information officer. Prior to that he held executive and senior positions at Portera Systems, eBay, and Sun Microsystems.